Lovage's Antimicrobial Activity — From the Kitchen Garden to Drug-Resistant Pathogens
This is the deepest vein of laboratory evidence lovage has produced — real, quantified, multi-laboratory antibacterial and antifungal data, including a lovage extract that strengthened an old antibiotic's activity against Salmonella in a laboratory screen, and a separate finding of real activity against the bacterium that causes tuberculosis. It is also entirely a test-tube story: nobody has ever tested whether eating lovage, or drinking a tea made from it, treats an infection in a living person. Both halves of that sentence are true at once, and this page holds them together rather than picking one.
Table of Contents
- A Traditional Infection-Fighting Reputation Meets a Modern Screening Program
- The Phthalide Antibacterial Data
- Efflux-Pump Synergy: Making an Old Antibiotic Work Again
- Against Drug-Resistant Tuberculosis
- Antifungal Activity
- Doing the Arithmetic: From a Test Tube to a Teaspoon
- What Has Never Been Tested: Zero Human Infection Trials
- Practical Bottom Line
- Key Research Papers
- Connections
- Featured Videos
A Traditional Infection-Fighting Reputation Meets a Modern Screening Program
Lovage's traditional reputation as a wound herb and a general "purifying" plant long predates any understanding of bacteria, but modern phytochemistry has taken that reputation seriously enough to actually screen the plant's extracts and isolated compounds against real bacterial, mycobacterial, and fungal panels. The resulting literature, concentrated in the last decade and a half, is genuinely more substantial and more specific than the diffuse folk reputation that motivated it — several independent research groups, working with different extraction methods and different pathogen panels, keep finding real activity.
The Phthalide Antibacterial Data
A 2020 phytochemistry study isolated three phthalide compounds from lovage root, including one newly described compound (7-methoxy-3-propylidenephthalide), and tested all three against a small panel of clinically relevant bacteria. One of the three showed real, quantifiable activity:
| Organism | Type | Minimum inhibitory concentration (MIC) of active lovage-root phthalide |
|---|---|---|
| Staphylococcus aureus | Gram-positive | 16 µg/mL |
| Escherichia coli | Gram-negative | 64 µg/mL |
| Vancomycin-resistant Enterococcus faecium (VRE) | Gram-positive, drug-resistant | 128 µg/mL |
The VRE result is the one worth pausing on: this is an isolated plant compound showing measurable activity against a specific, named, clinically important drug-resistant organism — not a vague "antibacterial extract" claim. It is still, in context, a modest number: 128 µg/mL is a workable in-vitro concentration for a screening assay, not a benchmark that competes with a modern antibiotic's typical potency, which is often active in the low single-digit µg/mL range or lower. What it establishes is a genuine, specific, structurally characterized lead compound, not a finished antimicrobial.
Efflux-Pump Synergy: Making an Old Antibiotic Work Again
A more mechanistically interesting result comes from a 2011 screening study that tested a lovage root extract not for its own antibacterial killing power, but for its ability to inhibit bacterial efflux pumps — the membrane transporters that many multidrug-resistant bacteria use to pump antibiotics back out of the cell before the drug can work. Out of 84 plant extracts from 21 species screened for synergy with the antibiotic ciprofloxacin against Salmonella enterica serotype Typhimurium — including mutant strains in which parts of the AcrAB-TolC efflux pump (the acrB and tolC genes) had been inactivated — the chloroform extract of lovage root was the single most active extract identified. Of the 84 extracts, 12 showed synergy with ciprofloxacin, and 2 of those had activity suggesting efflux inhibition. The most active extracts, fractions and purified compounds were then tested with five antibiotics against Enterobacteriaceae and Pseudomonas aeruginosa.
From the two lovage fractions that showed the greatest synergy with the five antibiotics, the researchers isolated falcarindiol — the same polyacetylene that turns up in the tuberculosis work below — together with the fatty acids oleic acid and linoleic acid. These fractions and compounds had antibacterial activity of their own, especially against mutants lacking a component of the AcrAB-TolC pump.
The important limitation, reported directly by the study's own authors: this synergy required the whole extract, and disappeared when the extract was fractionated down to individual purified compounds. That means the effect depends on some combination of substances acting together, not a single identifiable active molecule — scientifically real, but harder to standardize, reproduce as a supplement, or eventually develop into a defined drug than a single-compound finding would be.
Against Drug-Resistant Tuberculosis
Two independent studies, roughly a decade apart, both tested lovage-derived material against mycobacteria and both found real activity. A 2008 study extracted the roots with dichloromethane and, after bioassay-guided fractionation, identified two active polyacetylene compounds: 3(R)-falcarinol, with a minimum inhibitory concentration of 16.4 µM against both Mycobacterium fortuitum and Mycobacterium aurum, and 3(R)-8(S)-falcarindiol, with MICs of 30.7 µM against M. fortuitum and 61.4 µM against M. aurum. For comparison, the study's abstract reports that the reference antibiotics “ethambutol and isoniazid exhibited an activity of 115.5 microM and 14.6 microM against M. fortuitum, and 3.4 microM and 29.2 microM against M. aurum, respectively.”
A 2018 follow-up study went further, testing the hydro-distilled essential oil of lovage's leaves and stems (the aerial parts) directly against multidrug-resistant Mycobacterium tuberculosis — the actual human tuberculosis pathogen, in its drug-resistant form, rather than the faster-growing non-tuberculous mycobacteria used in most preliminary screens. The essential oil, whose major components were identified as α-terpinenyl acetate, β-phellandrene, and neocnidilide, showed a minimum inhibitory concentration (MIC) of 252 µg/mL against MDR-TB. Molecular docking modeling in the same study suggested the oil's major compounds bind an enzyme (InhA, 2-trans-enoyl-ACP reductase) central to the mycobacterial cell wall's fatty-acid synthesis pathway — the same general pathway isoniazid itself targets — with an affinity the authors describe as comparable to isoniazid in the docking model, though a docking simulation is a computational prediction, not a measured binding or clinical result.
A third study, a 2022 laboratory screen of 85 commercial essential oils, reported broad-spectrum antimycobacterial activity for two of them, cinnamon bark oil and lovage oil. Lovage oil had minimum inhibitory concentrations of 0.50, 0.5, 0.5 and 0.004 mg/mL against M. smegmatis, M. fortuitum, M. gordonae and M. tuberculosis, respectively.
All three findings are real, all are specific to lovage, and all are exclusively in-vitro laboratory results. Nothing here has been tested in an animal model of tuberculosis infection, let alone a human one, and MDR-TB remains a disease treated with a defined, monitored, multi-drug pharmaceutical regimen — not a condition where a kitchen herb has any established role.
Antifungal Activity
The same polyacetylene class active against mycobacteria — falcarindiol in particular — also shows antifungal activity in laboratory assays, inhibiting spore germination of several plant-pathogenic fungi (Botrytis cinerea, Cladosporium herbarum, Fusarium avenaceum) at concentrations in the 12–50 µg/mL range, and falcarindiol-type polyacetylenes are recognized more broadly across the Apiaceae family as natural plant-defense compounds (phytoalexins) that plants themselves produce in response to fungal attack. This is consistent, mechanistically coherent laboratory evidence for a real antifungal property of lovage's chemistry. Lovage leaf extracts have also been tested against the yeast Candida albicans: in a 2021 laboratory study, the most active extracts (ethanol extracts of microwave-dried leaves) had a minimal inhibitory concentration (MIC) of 0.625 mg/mL and a minimal lethal concentration of 1.25 mg/mL. There is no clinical antifungal-use tradition for lovage to compare it against — this is a laboratory finding awaiting a clinical question, not an answer to one that was already being asked.
Doing the Arithmetic: From a Test Tube to a Teaspoon
It is worth translating the minimum inhibitory concentration numbers above into something closer to a kitchen quantity, the way this site does for other herbs with in-vitro antimicrobial data, because the gap is usually much larger than a supplement label implies. Take the VRE result: 128 µg/mL is 128 milligrams of active phthalide per liter of solution bathing bacteria directly in a test tube — a concentration achieved by dissolving a purified, isolated compound at a controlled concentration, not by drinking tea. Lovage root itself is not pure phthalide; the essential oil content of the whole root runs roughly 0.6–1% by weight, and the specific antibacterial phthalide identified in the 2020 study is only one minor fraction of that oil. Reaching a systemic concentration in a human body anywhere near an in-vitro minimum inhibitory concentration, from a food-quantity dose of the whole herb, would require amounts far beyond normal culinary or even typical traditional-tea use — before accounting for the fact that the oral bioavailability of these phthalides is itself limited (a related compound, ligustilide, had an oral bioavailability of only 2.6% in a rat pharmacokinetic study — that is, only about 2.6% of an oral dose reached the bloodstream — partly because of extensive first-pass metabolism in the liver).
None of this erases the laboratory finding. It means the honest translation of "lovage root contains a compound active against VRE at 128 µg/mL in a dish" is "a real, structurally identified antibacterial lead compound exists in this plant," not "eating lovage fights drug-resistant infections" — the arithmetic between those two claims has never been closed by anyone testing whole-herb doses in a living organism.
What Has Never Been Tested: Zero Human Infection Trials
Stated as its own finding, because absence of evidence is itself informative here, not merely a caveat: there is no controlled trial, case series, or even a single published case report of lovage root, leaf, or extract being used to treat a bacterial, fungal, or mycobacterial infection in a human being. The only human clinical data connecting lovage to infection at all is a commercial multi-herb kidney product containing lovage, discussed on the diuretic and urinary tract page, where lovage is one of three ingredients in a product studied for urinary tract infection prevention — useful context, but not evidence for lovage's antimicrobial activity in isolation, and that formula's apparent benefit has never been mechanistically tied back to the specific antibacterial phthalides or polyacetylenes described on this page.
This gap exists despite the antimicrobial laboratory work being both real and, in the efflux-pump and tuberculosis findings especially, more specific and mechanistically interesting than most kitchen-herb antimicrobial claims on this site. The honest conclusion is that this is exactly the kind of early-stage finding — a real hit in a screening assay, with a plausible mechanism — that either goes on to be developed into something clinically tested over the following decade, or quietly stays a laboratory curiosity forever. Nothing published so far tells you which fate awaits lovage's antimicrobial chemistry.
Practical Bottom Line
Lovage has never been tested as a treatment for any infection in people, tuberculosis included — nothing in this evidence base has been tested at that level, and a serious infection whose proven treatment is delayed on the strength of a test-tube finding can become genuinely dangerous. What the evidence does support is a scientifically legitimate reason for continued research interest: multiple independent laboratories, using different methods, keep finding real, structurally identified antimicrobial activity in this plant, including against organisms — VRE, Salmonella, and multidrug-resistant tuberculosis (MDR-TB) — that matter a great deal in modern medicine. That is a genuinely more substantial laboratory story than most of the claims made about this herb, and it is also, so far, entirely a laboratory story.
Key Research Papers
- Miran M, Monsef Esfahani H, Jung JH, et al. Characterization and Antibacterial Activity of Phthalides from the Roots of the Medicinal Herb Levisticum officinale W.D.J. Koch (2020). Iranian Journal of Pharmaceutical Research. — PubMed PMID: 33224223 — Source of the S. aureus / E. coli / VRE MIC table above.
- Garvey MI, Rahman MM, Gibbons S, Piddock LJ. Medicinal plant extracts with efflux inhibitory activity against Gram-negative bacteria (2011). International Journal of Antimicrobial Agents. — PubMed PMID: 21194895 — Lovage root extract as most active of 84 extracts screened; ciprofloxacin synergy data.
- Miran M, Feizabadi MM, Kazemian H, et al. The activity of Levisticum officinale W.D.J. Koch essential oil against multidrug-resistant Mycobacterium tuberculosis (2018). Iranian Journal of Microbiology. — PubMed PMID: 30873267
- Schinkovitz A, Stavri M, Gibbons S, Bucar F. Antimycobacterial polyacetylenes from Levisticum officinale (2008). Phytotherapy Research. — PubMed PMID: 18350523 — Source of the falcarinol and falcarindiol MIC data compared against ethambutol and isoniazid.
- Jakubczyk A, Złotek U, Rybczyńska-Tkaczyk K. Influence of Elicitation and Drying Methods on Anti-Metabolic Syndrome, and Antimicrobial Properties of Extracts and Hydrolysates Obtained from Elicited Lovage (2021). Nutrients. — PubMed PMID: 34959917
- Jakubczyk A, Złotek U, Szymanowska U, et al. In vitro Antioxidant, Anti-inflammatory, Anti-metabolic Syndrome, Antimicrobial, and Anticancer Effect of Phenolic Acids Isolated from Fresh Lovage Leaves (2020). Antioxidants. — PubMed PMID: 32630448
- Boussamba-Digombou KJ, Sandasi M, Kamatou GP, et al. Investigating the Antituberculosis Activity of Selected Commercial Essential Oils and Identification of Active Constituents Using a Biochemometrics Approach and In Silico Modeling (2022). Antibiotics. — PubMed PMID: 35884202
- Ciocarlan A, Dragalin I, Aricu A, et al. Chemical composition and antimicrobial activity of the Levisticum officinale W.D.J. Koch essential oil (2018). Chemistry Journal of Moldova. — doi:10.19261/cjm.2018.514
- Naber KG. Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease (2013). Research and Reports in Urology. — PubMed PMID: 24400233 — The only human infection-related clinical data connected to lovage, in a three-herb formula.
- Xie Q, Zhang L, Xie L, et al. Z-ligustilide: a review of its pharmacokinetics and pharmacology (2020). Phytotherapy Research. — PubMed PMID: 32135035 — Review describing ligustilide's poor oral bioavailability in rats due to first-pass metabolism.
- Yan R, Ko NL, Li SL, Tam YK, Lin G. Pharmacokinetics and metabolism of ligustilide, a major bioactive component in Rhizoma Chuanxiong, in the rat (2008). Drug Metabolism and Disposition. — PubMed PMID: 18039808 — Source of the 2.6% oral-bioavailability figure used in the arithmetic section.